Fundamental Analysis of IBIO INC(NYSEARCA:IBIO) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to IBIO. IBIO was compared to 588 industry peers in the Biotechnology industry. IBIO has a bad profitability rating. Also its financial health evaluation is rather negative. IBIO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IBIO has reported negative net income.

IBIO had a negative operating cash flow in the past year.

IBIO had negative earnings in each of the past 5 years.

In the past 5 years IBIO always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -80.19%, IBIO is not doing good in the industry: 71.40% of the companies in the same industry are doing better.

The Return On Equity of IBIO (-296.63%) is worse than 74.14% of its industry peers.

		Industry Rank	Sector Rank
ROA	-80.19%
ROE	-296.63%
ROIC	N/A

ROA(3y)-74.82%

ROA(5y)-64.68%

ROE(3y)-174.37%

ROE(5y)-260.94%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IBIO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, IBIO has more shares outstanding

IBIO has more shares outstanding than it did 5 years ago.

The debt/assets ratio for IBIO is higher compared to a year ago.

2.2 Solvency

IBIO has an Altman-Z score of -13.57. This is a bad value and indicates that IBIO is not financially healthy and even has some risk of bankruptcy.

IBIO has a Altman-Z score of -13.57. This is amonst the worse of the industry: IBIO underperforms 81.16% of its industry peers.

IBIO has a Debt/Equity ratio of 1.42. This is a high value indicating a heavy dependency on external financing.

IBIO's Debt to Equity ratio of 1.42 is on the low side compared to the rest of the industry. IBIO is outperformed by 80.48% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.42
Debt/FCF	N/A
Altman-Z	-13.57

ROIC/WACCN/A

WACC5.21%

2.3 Liquidity

IBIO has a Current Ratio of 0.91. This is a bad value and indicates that IBIO is not financially healthy enough and could expect problems in meeting its short term obligations.

The Current ratio of IBIO (0.91) is worse than 89.55% of its industry peers.

IBIO has a Quick Ratio of 0.91. This is a bad value and indicates that IBIO is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.91, IBIO is not doing good in the industry: 88.70% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.91
Quick Ratio	0.91

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for IBIO have decreased strongly by -97.37% in the last year.

Looking at the last year, IBIO shows a very negative growth in Revenue. The Revenue has decreased by -97.22% in the last year.

EPS 1Y (TTM)-97.37%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q93.54%

Revenue 1Y (TTM)-97.22%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, IBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 37.89% on average per year.

The Revenue is expected to grow by 100.00% on average over the next years. This is a very strong growth

EPS Next Y78.29%

EPS Next 2Y37.89%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year60%

Revenue Next 2Y100%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IBIO. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IBIO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

IBIO's earnings are expected to grow with 37.89% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.89%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IBIO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IBIO INC

NYSEARCA:IBIO (4/26/2024, 9:33:38 AM)

1.75

+0.03 (+1.74%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap14.91M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-80.19%
ROE	-296.63%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	1.42
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.91
Quick Ratio	0.91
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-97.37%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y78.29%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-97.22%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

IBIO INC (IBIO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens